F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: A systematic review

被引：47

作者：

Milly A Schröer-Günther

Robert F Wolff

Marie E Westwood

Fülöp J Scheibler

Christoph Schürmann

Brigitta G Baumert

Stefan Sauerland

Jos Kleijnen

机构：

[1] Institute for Quality and Efficiency in Health Care, Cologne 50670

[2] Kleijnen Systematic Reviews Ltd, Unit 6, Escrick, York YO19 6FD, Escrick Business Park Riccall Road

[3] School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, ER 6229

[4] Department of Radiation-Oncology (MAASTRO), GROW (School for Oncology and Developmental Biology), Maastricht University Medical Center, Maastricht, MD 6200

来源：

Systematic Reviews | / 1卷 / 1期

关键词：

Computed tomography; Esophageal neoplasms; Positron emission tomography; Recurrence; Staging; Systematic review;

D O I：

10.1186/2046-4053-1-62

中图分类号：

学科分类号：

摘要：

Purpose: The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma.Materials and methods: For the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool.Results: No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%.Conclusion: There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages. © 2012 Schröer-Günther et al.; licensee BioMed Central Ltd.

引用

共 47 条

[1] Guidance on Cancer Services: Improving Outcomes for People with Skin Tumours including Melanoma
[2] The Manual, Vol. 2009, (2006)
[3] Garbe C., Peris K., Hauschild A., Saiag P., Midddleton M., Spatz A., Grob J.J., Malvehy J., Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline, Eur J Cancer Clin Oncol, 46, pp. 270-283, (2010)
[4] Diagnosis and Treatment of Melanoma: European Consensus-based Interdisciplinary Guideline
[5] Dummer R., Hauschild A., Pentheroudakis G., Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, 20, SUPPL. 4, pp. 129-131, (2009)
[6] Saiag P., Bosquet L., Guillot B., Verola O., Avril M.F., Bailly C., Cupissol D., Dalac S., Danino A., Dreno B., Grob J.J., Leccia M.T., Renaud-Vilmer C., Negrier S., de Dermatologie S.F., Management of adult patients with cutaneous melanoma without distant metastasis: 2005 update of the French standards, options and recommendations guidelines
[7] summary report, Eur J Dermatol, 17, pp. 325-331, (2007)
[8] Marsden J.R., Newton-Bishop J.A., Burrows L., Cook M., Corrie P.G., Cox N.H., Gore M.E., Lorigan P., MacKie R., Nathan P., Peach H., Powell B., Walker C., Revised U.K. guidelines for the management of cutaneous melanoma, Br J Dermatol, 163, pp. 238-256, (2010)
[9] Allgemeine Methoden: Version 4.0
[10] Positronenemissionstomographie (PET und PET/CT) bei malignen Melanom

← 1 2 3 4 5 →